Eurazeo (RF) - Total Liabilities
Based on the latest financial reports, Eurazeo (RF) has total liabilities worth €1.70 Billion EUR (≈ $1.98 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eurazeo - Total Liabilities Trend (2003–2025)
This chart illustrates how Eurazeo's total liabilities have evolved over time, based on quarterly financial data. See RF working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Eurazeo Competitors by Total Liabilities
The table below lists competitors of Eurazeo ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kennametal Inc
NYSE:KMT
|
USA | $1.24 Billion |
|
Xianhe Co Ltd
SHG:603733
|
China | CN¥16.96 Billion |
|
Dongguan Aohai Technology Co
SHE:002993
|
China | CN¥5.57 Billion |
|
ATS CORP.
F:ATO0
|
Germany | €2.70 Billion |
|
China World Trade Center Co Ltd
SHG:600007
|
China | CN¥1.74 Billion |
|
Mtar Technologies Limited
NSE:MTARTECH
|
India | Rs4.30 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $112.59 Million |
|
ACC Limited
NSE:ACC
|
India | Rs69.71 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Eurazeo's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Eurazeo stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eurazeo's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eurazeo (2003–2025)
The table below shows the annual total liabilities of Eurazeo from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.70 Billion ≈ $1.98 Billion |
-9.32% |
| 2024-12-31 | €1.87 Billion ≈ $2.19 Billion |
+32.47% |
| 2023-12-31 | €1.41 Billion ≈ $1.65 Billion |
-85.25% |
| 2022-12-31 | €9.57 Billion ≈ $11.19 Billion |
+20.69% |
| 2021-12-31 | €7.93 Billion ≈ $9.27 Billion |
+2.65% |
| 2020-12-31 | €7.73 Billion ≈ $9.04 Billion |
+6.07% |
| 2019-12-31 | €7.29 Billion ≈ $8.52 Billion |
+24.68% |
| 2018-12-31 | €5.84 Billion ≈ $6.83 Billion |
+4.92% |
| 2017-12-31 | €5.57 Billion ≈ $6.51 Billion |
+8.27% |
| 2016-12-31 | €5.14 Billion ≈ $6.01 Billion |
+95.79% |
| 2015-12-31 | €2.63 Billion ≈ $3.07 Billion |
-70.10% |
| 2014-12-31 | €8.79 Billion ≈ $10.27 Billion |
-0.46% |
| 2013-12-31 | €8.83 Billion ≈ $10.32 Billion |
-13.50% |
| 2012-12-31 | €10.21 Billion ≈ $11.93 Billion |
-4.44% |
| 2011-12-31 | €10.68 Billion ≈ $12.49 Billion |
+4.41% |
| 2010-12-31 | €10.23 Billion ≈ $11.96 Billion |
-5.20% |
| 2009-12-31 | €10.79 Billion ≈ $12.62 Billion |
-3.47% |
| 2008-12-31 | €11.18 Billion ≈ $13.07 Billion |
+3.07% |
| 2007-12-31 | €10.85 Billion ≈ $12.68 Billion |
+2204.45% |
| 2003-12-31 | €470.68 Million ≈ $550.27 Million |
-- |
About Eurazeo
Eurazeo SE is a private equity and venture capital firm specializing in growth capital, series C, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in upper mid-market, mid-market and listed public companies, small- and mid-cap healthcare companies, equity in the small-mid and mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, … Read more